The serum concentration of infliximab in cases of autologous blood donation for patients with rheumatoid arthritis

Takeshi Mochizuki, Shigeki Momohara, Katsunori Ikari, Hiroshi Okamoto, Shu Kobayashi, So Tsukahara, Takuji Iwamoto, Koichiro Kawamura, Seiji Saito, Taisuke Tomatsu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Our aim was to determine whether the use of infliximab for rheumatoid arthritis (RA) patients is associated with an increased rate of postoperative complications. In this study we evaluated the serum concentration of infliximab to study the influence of autologous blood donation (AB donation) in patients who were administered infliximab and underwent total knee replacement (TKR). We examined five RA patients. Infliximab combined with methotrexate was administered at 3 mg/kg every 8 weeks for all patients. We carried out the TKR operation in the middle of the 8-week interval in which infliximab was administered. The AB donation consisted of 400 ml pooled AB drawn at one point 2 weeks following the final administration of infliximab. Serum infliximab levels were measured using an enzyme-linked immunosorbent assay. Mean serum infliximab levels were 5.46 ± 5.62μg/ml 2 weeks after the final administration of infliximab, 2.02 ± 1.66 μg/ml just before the operation, and 1.48 ± 1.31μg/ml 1 day post operation. Moreover, the mean serum level in an autologous blood bag sampled just before AB donation was 5.02 ± 4.79 μg/ml. This study indicated the serum level of infliximab in the stored blood remained at almost the same level as the collected autologous blood. However, even after autotransfusion those levels were decreased compared with levels measured just before the operation. Therefore, we conclude that there is little influence of AB donation on the risks of infliximab.

Original languageEnglish
Pages (from-to)24-27
Number of pages4
JournalModern Rheumatology
Volume17
Issue number1
DOIs
Publication statusPublished - 2007 Feb
Externally publishedYes

Fingerprint

Blood Donors
Rheumatoid Arthritis
Serum
Knee Replacement Arthroplasties
Infliximab
Autologous Blood Transfusions
Methotrexate
Enzyme-Linked Immunosorbent Assay

Keywords

  • Autologous blood donation
  • Infliximab
  • Orthopaedic surgery
  • Rheumatoid arthritis
  • Total knee replacement

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

The serum concentration of infliximab in cases of autologous blood donation for patients with rheumatoid arthritis. / Mochizuki, Takeshi; Momohara, Shigeki; Ikari, Katsunori; Okamoto, Hiroshi; Kobayashi, Shu; Tsukahara, So; Iwamoto, Takuji; Kawamura, Koichiro; Saito, Seiji; Tomatsu, Taisuke.

In: Modern Rheumatology, Vol. 17, No. 1, 02.2007, p. 24-27.

Research output: Contribution to journalArticle

Mochizuki, T, Momohara, S, Ikari, K, Okamoto, H, Kobayashi, S, Tsukahara, S, Iwamoto, T, Kawamura, K, Saito, S & Tomatsu, T 2007, 'The serum concentration of infliximab in cases of autologous blood donation for patients with rheumatoid arthritis', Modern Rheumatology, vol. 17, no. 1, pp. 24-27. https://doi.org/10.1007/s10165-006-0539-6
Mochizuki, Takeshi ; Momohara, Shigeki ; Ikari, Katsunori ; Okamoto, Hiroshi ; Kobayashi, Shu ; Tsukahara, So ; Iwamoto, Takuji ; Kawamura, Koichiro ; Saito, Seiji ; Tomatsu, Taisuke. / The serum concentration of infliximab in cases of autologous blood donation for patients with rheumatoid arthritis. In: Modern Rheumatology. 2007 ; Vol. 17, No. 1. pp. 24-27.
@article{ebbc3e3e841542dd9980b3f43c4e92de,
title = "The serum concentration of infliximab in cases of autologous blood donation for patients with rheumatoid arthritis",
abstract = "Our aim was to determine whether the use of infliximab for rheumatoid arthritis (RA) patients is associated with an increased rate of postoperative complications. In this study we evaluated the serum concentration of infliximab to study the influence of autologous blood donation (AB donation) in patients who were administered infliximab and underwent total knee replacement (TKR). We examined five RA patients. Infliximab combined with methotrexate was administered at 3 mg/kg every 8 weeks for all patients. We carried out the TKR operation in the middle of the 8-week interval in which infliximab was administered. The AB donation consisted of 400 ml pooled AB drawn at one point 2 weeks following the final administration of infliximab. Serum infliximab levels were measured using an enzyme-linked immunosorbent assay. Mean serum infliximab levels were 5.46 ± 5.62μg/ml 2 weeks after the final administration of infliximab, 2.02 ± 1.66 μg/ml just before the operation, and 1.48 ± 1.31μg/ml 1 day post operation. Moreover, the mean serum level in an autologous blood bag sampled just before AB donation was 5.02 ± 4.79 μg/ml. This study indicated the serum level of infliximab in the stored blood remained at almost the same level as the collected autologous blood. However, even after autotransfusion those levels were decreased compared with levels measured just before the operation. Therefore, we conclude that there is little influence of AB donation on the risks of infliximab.",
keywords = "Autologous blood donation, Infliximab, Orthopaedic surgery, Rheumatoid arthritis, Total knee replacement",
author = "Takeshi Mochizuki and Shigeki Momohara and Katsunori Ikari and Hiroshi Okamoto and Shu Kobayashi and So Tsukahara and Takuji Iwamoto and Koichiro Kawamura and Seiji Saito and Taisuke Tomatsu",
year = "2007",
month = "2",
doi = "10.1007/s10165-006-0539-6",
language = "English",
volume = "17",
pages = "24--27",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - The serum concentration of infliximab in cases of autologous blood donation for patients with rheumatoid arthritis

AU - Mochizuki, Takeshi

AU - Momohara, Shigeki

AU - Ikari, Katsunori

AU - Okamoto, Hiroshi

AU - Kobayashi, Shu

AU - Tsukahara, So

AU - Iwamoto, Takuji

AU - Kawamura, Koichiro

AU - Saito, Seiji

AU - Tomatsu, Taisuke

PY - 2007/2

Y1 - 2007/2

N2 - Our aim was to determine whether the use of infliximab for rheumatoid arthritis (RA) patients is associated with an increased rate of postoperative complications. In this study we evaluated the serum concentration of infliximab to study the influence of autologous blood donation (AB donation) in patients who were administered infliximab and underwent total knee replacement (TKR). We examined five RA patients. Infliximab combined with methotrexate was administered at 3 mg/kg every 8 weeks for all patients. We carried out the TKR operation in the middle of the 8-week interval in which infliximab was administered. The AB donation consisted of 400 ml pooled AB drawn at one point 2 weeks following the final administration of infliximab. Serum infliximab levels were measured using an enzyme-linked immunosorbent assay. Mean serum infliximab levels were 5.46 ± 5.62μg/ml 2 weeks after the final administration of infliximab, 2.02 ± 1.66 μg/ml just before the operation, and 1.48 ± 1.31μg/ml 1 day post operation. Moreover, the mean serum level in an autologous blood bag sampled just before AB donation was 5.02 ± 4.79 μg/ml. This study indicated the serum level of infliximab in the stored blood remained at almost the same level as the collected autologous blood. However, even after autotransfusion those levels were decreased compared with levels measured just before the operation. Therefore, we conclude that there is little influence of AB donation on the risks of infliximab.

AB - Our aim was to determine whether the use of infliximab for rheumatoid arthritis (RA) patients is associated with an increased rate of postoperative complications. In this study we evaluated the serum concentration of infliximab to study the influence of autologous blood donation (AB donation) in patients who were administered infliximab and underwent total knee replacement (TKR). We examined five RA patients. Infliximab combined with methotrexate was administered at 3 mg/kg every 8 weeks for all patients. We carried out the TKR operation in the middle of the 8-week interval in which infliximab was administered. The AB donation consisted of 400 ml pooled AB drawn at one point 2 weeks following the final administration of infliximab. Serum infliximab levels were measured using an enzyme-linked immunosorbent assay. Mean serum infliximab levels were 5.46 ± 5.62μg/ml 2 weeks after the final administration of infliximab, 2.02 ± 1.66 μg/ml just before the operation, and 1.48 ± 1.31μg/ml 1 day post operation. Moreover, the mean serum level in an autologous blood bag sampled just before AB donation was 5.02 ± 4.79 μg/ml. This study indicated the serum level of infliximab in the stored blood remained at almost the same level as the collected autologous blood. However, even after autotransfusion those levels were decreased compared with levels measured just before the operation. Therefore, we conclude that there is little influence of AB donation on the risks of infliximab.

KW - Autologous blood donation

KW - Infliximab

KW - Orthopaedic surgery

KW - Rheumatoid arthritis

KW - Total knee replacement

UR - http://www.scopus.com/inward/record.url?scp=34247612482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247612482&partnerID=8YFLogxK

U2 - 10.1007/s10165-006-0539-6

DO - 10.1007/s10165-006-0539-6

M3 - Article

VL - 17

SP - 24

EP - 27

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 1

ER -